CAJ | 학술논문

目的：：评价脱氧核苷酸钠短期大剂量干预实体肿瘤化疗所引起骨髓抑制及肝脏损伤的有效性及安全性,并评价脱氧核苷酸钠对肿瘤细胞生长的影响。方法：86例肺癌、胃癌、结直肠癌、肝癌患者,随机分为对照组和观察组各43例。两组均采用常规化疗方案,观察组在化疗基础上给予脱氧核苷酸钠200 mg,ivd,qd。化疗后评价两组患者骨髓抑制、肝功能和体质量情况。结果：观察组与对照组总有效率分别为47.5%,44.9%,差异无统计学意义(P>0.05)。观察组患者III~IV度骨髓抑制发生率为20.0%,明显低于对照组的58.5%(P<0.05)；CD3+、CD4+、NK细胞水平均高于对照组(P<0.01)。两组肝功能异常发生率分别为27.5%、65.8%,差异有统计学意义(P<0.01)。化疗后,观察组患者体质量明显高于对照组(P<0.05)。结论：脱氧核苷酸可以减轻化疗所导致的骨髓抑制及肝功能的损伤,促进患者体质量恢复。
목적：：평개탈양핵감산납단기대제량간예실체종류화료소인기골수억제급간장손상적유효성급안전성,병평개탈양핵감산납대종류세포생장적영향。방법：86례폐암、위암、결직장암、간암환자,수궤분위대조조화관찰조각43례。량조균채용상규화료방안,관찰조재화료기출상급여탈양핵감산납200 mg,ivd,qd。화료후평개량조환자골수억제、간공능화체질량정황。결과：관찰조여대조조총유효솔분별위47.5%,44.9%,차이무통계학의의(P>0.05)。관찰조환자III~IV도골수억제발생솔위20.0%,명현저우대조조적58.5%(P<0.05)；CD3+、CD4+、NK세포수평균고우대조조(P<0.01)。량조간공능이상발생솔분별위27.5%、65.8%,차이유통계학의의(P<0.01)。화료후,관찰조환자체질량명현고우대조조(P<0.05)。결론：탈양핵감산가이감경화료소도치적골수억제급간공능적손상,촉진환자체질량회복。
Objective:To evaluate the efficacy and safety of deoxyribonucleotide in intervention with solid tumor. Methods:A exper-imental study and randomized clinical trial were conducted. Experimental study part: MTT assay and S-180 sarcoma method were launched to observe whether the deoxyribonucleotide would affect the tumor growth. Clinical study part:86 patients of lung cancer, gastric cancer, colorectal cancer, liver cancer were divided into control group(n=43) and treatment group (n=43). Both group were given routine therapy,and the treatment group were given deoxyribonucleotide at the same time. Bone marrow suppression and live function were assessed after chemotherapy. Results:Chemotherapy Clinical effect did not improved in Deoxyribonucleotide group (47. 5% vs 44. 9%, P>0. 05), however, theⅢ-Ⅳbone,NKcellswere improved by deoxyribonucleotide (P<0. 05). What is more, the live injury of treat-ment group were less than the control group. Conclusion:Deoxyribonucleotide can decrese the occurace rate of live injury and bone mar-row suppression.